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Abstract
Background: While it is accepted that a majority of invasive breast cancer progresses from a ductal carcinoma in situ (DCIS)
precursor stage, very little is known about the factors that promote survival of DCIS neoplastic cells within the hypoxic,
nutrient deprived intraductal microenvironment.
Methodology and Principal Findings: We examined the hypothesis that fresh human DCIS lesions contain pre-existing
carcinoma precursor cells. We characterized these cells by full genome molecular cytogenetics (Illumina HumanCytoSNP
profile), and signal pathway profiling (Reverse Phase Protein Microarray, 59 endpoints), and demonstrated that autophagy is
required for survival and anchorage independent growth of the cytogenetically abnormal tumorigenic DCIS cells. Ex vivo
organoid culture of fresh human DCIS lesions, without enzymatic treatment or sorting, induced the emergence of neoplastic
epithelial cells exhibiting the following characteristics: a) spontaneous generation of hundreds of spheroids and duct-like 3-
D structures in culture within 2–4 weeks; b) tumorigenicity in NOD/SCID mice; c) cytogenetically abnormal (copy number
loss or gain in chromosomes including 1, 5, 6, 8, 13, 17) compared to the normal karyotype of the non-neoplastic cells in the
source patient’s breast tissue; d) in vitro migration and invasion of autologous breast stroma; and e) up-regulation of signal
pathways linked to, and components of, cellular autophagy. Multiple autophagy markers were present in the patient’s
original DCIS lesion and the mouse xenograft. We tested whether autophagy was necessary for survival of cytogenetically
abnormal DCIS cells. The lysosomotropic inhibitor (chloroquine phosphate) of autophagy completely suppressed the
generation of DCIS spheroids/3-D structures, suppressed ex vivo invasion of autologous stroma, induced apoptosis,
suppressed autophagy associated proteins including Atg5, AKT/PI3 Kinase and mTOR, eliminated cytogenetically abnormal
spheroid forming cells from the organ culture, and abrogated xenograft tumor formation.
Conclusions: Cytogenetically abnormal spheroid forming, tumorigenic, and invasive neoplastic epithelial cells pre-exist in
human DCIS and require cellular autophagy for survival.
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Introduction
While the transition from in situ to invasive cancer is central to the
origin of the malignant phenotype, very little is known about the time
of onset, and the triggering mechanism, that switches in situ
neoplastic lesions to overt invasive carcinoma in the human breast.
Ductal Carcinoma In Situ (DCIS), the most common type of non-
invasive breast cancer in women, is defined as a proliferation of
neoplastic epithelial cells within the duct that is normally surrounded
by myoepithelial cells and an intact basement membrane [1–3].
Between 1980 and 2001, the incidence rate of DCIS increased 7.2-
fold, presumably due to increasing compliance and improved
detection by mammography [1,3]. DCIS now accounts for an
estimated 30% of the 185,000 breast cancers detected by
mammography each year [4,5]. There is both clinical and
experimental evidence to suggest that DCIS is a precursor lesion to
most, if not all, invasive carcinoma. It is generally accepted that
women diagnosed with DCIS remain at high risk for subsequent
development of invasive carcinoma, with lesion size, degree of
nuclear atypia and the presence of comedo necrosis being
histopathological factors of DCIS identified as affecting this risk of
recurrence [6,7]. The critical unanswered biologic questions,
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neoplastic cells pre-exist in the pure intraductal DCIS lesion prior to
theoverthistologictransitiontoinvasivecarcinoma?Ifsuchprecursor
carcinoma cells pre-exist in DCIS, does autophagy support their
survival in the face of nutrient deprivation and hypoxia?
It has been previously hypothesized that breast cancer
progression is a multi-step process involving a continuum of
changes from the normal phenotype to hyperplastic lesions,
carcinomas in situ, invasive carcinoma, and finally to metastatic
disease [8]. Under this model additional genetic alterations are
required before neoplastic cells in a DCIS lesion can progress to an
invasive and metastatic carcinoma. However, more recent
refinements of this model indicate that the aggressive phenotype
of breast cancer is determined at the premalignant stage, much
earlier than previously thought. Experimental approaches em-
ploying loss-of-heterozygosity (LOH), and comparative genomic
hybridization (CGH) provide strong evidence that DCIS and
invasive carcinomas in the same patient share similar genetic
alterations [6,7,9,10]. Gene expression studies of patient-matched
tissues including atypical ductal hyperplasia (ADH), DCIS, and
invasive carcinoma revealed that the various stages of disease
progression are very similar to each other at the level of the
transcriptome [7,9,10]. These studies also show that the DCIS
lesions at the level of gene expression are more similar to the
invasive cancers in the same patient compared to DCIS lesions in
other patients [7,10]. Damonte et al employing the ‘MINO’
(mammary intraepithelial neoplasia outgrowth) mouse model of
DCIS concluded that malignant aggressiveness is pre-programmed
in the pre-cancer stem cell [6]. Taken together, these data support
the hypothesis that the invasive phenotype of breast cancer is
already programmed at the pre-invasive stages of disease
progression.
In the present study we studied the cellular processes that
promote the survival of the invasive precursor cells that exist
within the human breast intraductal niche. Living human DCIS
ducts were explanted into organoid culture, in serum free
conditions, to expose the putative DCIS neoplastic cells within
the duct. We characterized the biologic phenotype of these
emerging cells using xenograft transplantation, and propagation in
organ culture and evaluated the survival mechanisms employed by
these cells. Cytogenetically abnormal DCIS lesion derived
epithelial cells were identified by their phenotype of anchorage
independent growth as 3-D spheroids and duct like structures,
invasion of autologous stroma, and tumorigenicity in SCID NOD
mice. We find that autophagy is a principal, and perhaps
necessary, survival pathway in DCIS.
To date, the macroautophagy survival pathway (autophagy) has
not been implicated in the survival of malignant precursor cells
within human DCIS lesions. Autophagy (self-eating) is a dynamic,
catabolic process of organelle digestion that generates ATP during
periods of nutrient limitation [11–13]. Autophagy optimizes
nutrient utilization in growing cells faced with hypoxic or
metabolic stresses (Figure S1). During autophagy, macroautopha-
gosomes (also referred as autophagosomes) are formed as double
membrane-bound vesicles that engulf cytoplasmic constituents
and/or cytoplasmic organelles. Autophagosomes fuse with lyso-
somes to degrade the contents of the autophagic vesicle and
provide molecular break down products to either feed the cell or
enable cell death. Accumulation of autophagosomes can be due to
reduced turnover of autophagosomes or increased autophagic
activity [14]. Cancer cells may undergo autophagic cell death
associated with extreme autophagic degradation after exposure to
several cancer therapies [15]. While some initial studies described
autophagy as a tumor suppressor mechanism [16], the autophagic
response can also function as a protective mechanism allowing the
recycling of proteins and cellular components to facilitate cell
survival during the severe cellular stress of cytotoxic therapy [17].
It remains largely unknown whether ‘‘protective autophagy’’
might also sustain the survival of premalignant or malignant
progenitor cells with the intraductal environment of the DCIS
lesion. Proliferating DCIS epithelial cells accumulating within the
breast DCIS lesion are separated from the surrounding lymphatic
and vascular supply by the ductal epithelial basement membrane.
High grade DCIS is associated with central necrosis in the duct,
and the accumulation of cellular degradation products such as
lipofuschin. Autophagy is a plausible means for DCIS neoplastic
cells, accumulating in the duct, to survive in the face of severe
metabolic, oxidative, and hypoxic stress. We directly tested
whether autophagy was necessary for the survival of cytogeneti-
cally abnormal, tumorigenic DCIS cells by treating the DCIS cells
with the lysosomotropic inhibitor (chloroquine phosphate).
Results
Human DCIS cells are tumorigenic in NOD/SCID mouse
xenografts
The existence of tumorigenic cells within fresh human DCIS
duct segments was first tested using xenotransplantation [18].
Multiple independent xenograft transplants of human DCIS
organoids, with no histological evidence of invasive carcinoma,
generated tumors within 1 to 2 months in NOD SCID mice.
Xenograft transplants generated from invasive breast carcinoma
or DCIS with invasive components were used as positive controls.
The number of positive control tumors observed for mixed DCIS
or invasive breast carcinoma tissue was 9 of 20 transplanted (45%)
(data not shown). 56 mice were transplanted with either freshly
procured DCIS duct segments, propagated xenograft tumors, or
organoids and/or human primary cultured cells generated from
the DCIS tissue (Figure 1). The number of tumors generated
within 3 months of injection was 43/56. The number of tumors
observed for pure DCIS tissue, which included cribriform DCIS,
as well as DCIS Grades II and III, was 18 of 22 transplanted
(81%). Xenograft propagated tumors, which were derived initially
from pure DCIS tissue, produced tumors in 4 out of 5 mice for 2
generations (Figure 1 and Figure S2).
In order to identify and characterize the tumorigenic neoplastic
cells within the DCIS tissue that were responsible for the
tumorigenic phenotype observed in the mouse xenografts, we
cultured fresh living human DCIS ductal fragments to generate
DCIS neoplastic cell outgrowths. The outgrowths spontaneously
generated 3-D structures including spheroids and duct-like
structures (Figure 1D–F). The number of tumors observed from
cultured primary cells and/or spheroids was 21 of 27 transplanted
(77.7%). Xenograft tumors arising from pure DCIS tissue
contained partially formed ductal structures with stromal infiltra-
tion and were positive by immunofluorescence (IF) for human
specific epithelial cell adhesion molecule (EpCAM) (Figure 1G–I).
No evidence of organ metastasis was noted at necropsy. These
data clearly demonstrate that both DCIS tissue and cultured DCIS
spheroid structures were capable of inducing tumors with
comparable tumorigenic potential.
Anchorage independent neoplastic epithelial cells
spontaneously emerge in organ culture of human DCIS
Organoid culture was used to characterize the DCIS neoplastic
cells that were implicated in tumorigenesis by the xenograft
experiments. Migratory proliferative cells that were positive for
human specific EpCAM were observed to migrate out of the DCIS
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weeks). Continued in vitro organoid cultivation successfully
propagated DCIS derived epithelial cells with anchorage inde-
pendent growth, defined as upward growing and expanding
spheroids, and lobulated, duct-like 3-D formations with pseudo
lumens, in serum free medium supplemented with EGF and
insulin (Figure 1).
DCIS cultured neoplastic epithelial cells migrated over the
surface of autologous stroma and formed multilayered colonies
with clear epithelial morphology (Figure 1C). Invasive foci beneath
these outgrowths within autologous stroma were verified by
absence of type IV collagen basement membrane. Seven human
DCIS derived epithelial strains, capable of generating spheroids,
have been propagated and characterized to date, some for as long
as one year (Table 1). Sub-passage of DCIS organoids reconsti-
tuted the 3-D ductal and spheroid phenotypes, which reproducibly
invaded inward from the surface of autologous stroma in organoid
culture. The culture conditions consistently generated a high yield
of DCIS epithelial cell outgrowths for each patient, even with
small volumes of starting tissue.
DCIS derived tumorigenic spheroid forming cells are
cytogenetically abnormal
The genotype of the isolated DCIS spheroid forming cells was
evaluated and compared to the non-neoplastic tissue from the
same patient. The spheroid forming DCIS epithelial cells were
found to be cytogenetically abnormal compared to the normal
karyotype of the anchorage dependent monolayer cells cultured
from the same patient’s breast tissue lesion. Full genotypic data
output included allele calls from ‘‘tagged’’ single nucleotide
polymorphism (SNP) sites and signal intensity values from non-
polymorphic sites to determine DNA copy number values
(CytoSNP-12 beadchips (Illumina, Inc.). Molecular cytogenetic
profiles demonstrated cytogenetic alterations in the isolated DCIS
spheroids (3–5 spheroids per prep) and isolated pseudoductular
structures. The spheroid abnormal karyotype signature included
loss of copy number on chromosome 5, 6, 8, and 13, and gain of
copy number on chromosomes 1, 5, and 17. Abnormalities were
present in all DCIS cell spheroids and pseudoductular isolates
(Table 2) and arose in a background of cells with a normal
karyotype from the same patient.
Figure 1. Human DCIS tissue generates spheroids and pseudoductal structures in ex vivo culture and xenograft neoplasms. (A) H&E
stain of human breast DCIS, grade III with comedo necrosis (case 08-352), that represents the primary surgical source material for our organoid
culture model system (106). (B) DCIS cultured neoplastic cell exhibited autologous stromal invasion (206). (C) H&E stain of multi-layered pleomorphic
epithelial cells growing on the surface of autologous breast stroma after 12 weeks in culture (206). Organoid culture of human DCIS lesions in serum
free conditions spontaneously yielded (D) epithelial spheroids (106) with a single spheroid shown in (E) (406) and (F) pseudoductal structures with
lumen formation (206). (G) Human DCIS organoids or spheroids transplanted in NOD SCID mice induced tumor formation at the mammary fat pad
transplantation site within 2 months. Xenograft tumors were greater than 16 mm
2 (length x width) as measured with calipers. (H) H&E stain of murine
xenograft tumor (1006). Note pleomorphic epithelial cells with prominent nucleoli, stromal invasion and partial glandular differentiation. (I) Murine
xenograft tumors derived from human DCIS cells were shown to be of human origin by the presence of human-specific epithelial antigen in formalin
fixed paraffin embedded tissue sections. EpCAM-FITC (pseudo-colored green, 488 nm) and DAPI (psuedo-colored blue, 408 nm) (206objective).
doi:10.1371/journal.pone.0010240.g001
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of DNA .3 million base pairs. If gains or losses greater than 1
million base pairs were used as the cutoff, then, at this higher
resolution, anchorage independent spheroid cells from 3 different
patient DCIS lesions all showed narrow copy number loss of
chromosome 6 (p21.1/p12.3). This region includes the transcrip-
tion factor SUPT3H (protein coding GIFtS:59, GC06M044904,
UniProtKB/Swiss-Prot: SUPT3_HUMAN, O75486) (Figure S3).
A second region of aberration was observed in a single patient on
the p-arm of chromosome 5 entailing extended regions of gain and
loss of chromosomal content. Chromosomal bands from 5p12 to
5p13.3 were present in 3 copies and a distal segment of 5p13.3
included 4 copies. Bands 5p14.1 and 5p14.3 on the same
chromosome however showed loss of DNA content as represented
by homozygous and hemizygous deletions, respectively (Figure
S4). This same patient’s cultured DCIS cells showed a 14
Megabase (Mb) region of trisomy on chromosome 17, extending
from 17q22 to 17q25.1 (Figure S5). The SNP data indicated, for
all matched samples, that the DCIS cultured cells were derived
from the donor patient tissue and were not a contaminating cell
line. The normal epithelial and stromal cells of the donor tissue
grown for the same length of time in culture possessed a fully
normal karyotype, while in all cases the propagated DCIS cells
forming 3-D structures and exhibiting invasion exhibited genetic
copy number gain or loss derangements in one or more genetic
loci indicative of a neoplastic mutational event (Table 2, Figures
S3-S6). Multiple isolates from different regions of the DCIS lesion,
for the same patient, yielded spheroids with the same abnormal
molecular karyotype. Thus, cytogenetically abnormal, DCIS
derived, spheroid forming epithelial cells, emerged spontaneously
from organoids in culture and were responsible for the
tumorigenic and invasive phenotype observed (Figure 1).
Signal pathway proteomic analysis reveals augmentation
of survival related pathways
Within the organoid cultures we sought to characterize the
functional signal pathways that may be involved in the phenotype
of these cells. It would not be possible to measure a large number
of protein signal pathway endpoints and post-translational
modifications by conventional flow cytometry following enzymatic
dissociation, even within a hundred spheroids. Consequently we
used Reverse Phase Protein Microarray (RPMA) analysis of 59 cell
signaling kinase endpoints, representing stem cell markers,
autophagy, adhesion, invasion, and pro-survival pathways (Table
S1). RPMA technology has the required sensitivity and precision
for small numbers of cells and provides a means of quantifying
phosphoproteins indicative of activated signal pathways [19,20].
Comparison of the spheroids to the flat, single layer epithelial
cells in the same culture revealed a set of activated signaling
pathways consistent with a progenitor-type classification. Autoph-
agy markers (Atg5 and LC3B) were elevated in the spheroids in
comparison to the epithelial and cuboidal monolayer cells. p38
MAPK Thr180/Tyr182 and SMAD2 Ser465/467, cell signaling
proteins associated with survival and stress, were elevated in the
spheroids in comparison to the epithelial and cuboidal monolay-
ers. The spheroids exhibited progenitor cell characteristics as
evidenced by up-regulation of stem cell markers (CD44), down-
regulation of cell adhesion markers (E-Cadherin), up-regulation of
invasion related metalloproteinases (MMP14), and up-regulation
of COX-2 (Figure 2).
To test whether these differences in cell signaling proteins were a
stable characteristic of the observed phenotype, we conducted an
independent verification analysis. RPMA was performed on a
different set of harvested cultured spheroids, epithelial cells, and
stromal fibroblasts from the same patient derived cultures that were
propagated over several months (Table 1). Autophagy, adhesion, and
pro-survival signaling proteins remained elevated in the spheroids
compared to the epithelial and fibroblast cells (Table S2).
Autophagy is elevated in DCIS cells
Based on the RPMA phenotypic characterization, we noted that
cell signaling pathways intersecting with the autophagy pathway
were up-regulated in the cultured DCIS spheroids and 3-D
structures. Autophagy markers were found to be activated in
DCIS lesions in vivo, DCIS cultured organoids, and murine human
DCIS xenografts. Intermediate and high-grade DCIS lesions were
positive by immunohistochemistry for autophagy pathway proteins
Atg5, Beclin-1 and LC3B, which are involved in the nucleation of
autophagosomes (Table 3). Autophagosome accumulation, as
demonstrated by fluorescence microscopy and immunohistochem-
istry of endogenous LC3B, showed an increase in punctate LC3B,
a hallmark of autophagy because it is the first protein to associate
with the autophagosomal membrane (Figure 3) [14,21]. The
acidotropic dye, LysoTracker Red (Invitrogen), which accumulates
in intracellular organelle components associated with autophagy
(autophagosomoses/lysosomes), was used to image live DCIS
organoids culture cell outgrowths, including spheroids and 3-D
structures (Figure S1). In DCIS progenitor cells forming spheroids
Table 1. Patient characteristics for generation of ex vivo DCIS cultures.
Sample Age
Pathologic
Diagnosis Morphologic subtype Nuclear Grade
ER (%
positive) PR (% positive)
Time in ex vivo
culture (months)
08-183 47 DCIS CN/CR 3 30% Neg 6
08-352 42 DCIS CR-extended 3 50% 50% 12
09-091 68 DCIS/ADH CR 2/3 ++ 8
09-118 49 ADH* Stromal fibrosis-AH 2 + N/A 8
09-148 45 DCIS Solid and CR 3 90% 90% 7
09-301 34 DCIS Solid and CR 2 90% 90% 4
09-327 57 DCIS Cribriform with IP 2 ++ 2
DCIS=ductal carcinoma in situ; ADH=Atypical ductal hyperplasia; ER=Estrogen Receptor; PR=Progesterone Receptor; + indicates positive result, no cell percentage
specified;
*Previous history of DCIS, patient treated with Tamoxifen citrate; CN=Comedo necrosis; CR=Cribriform; CR-extended = extension into lobules with no evidence of
invasion; AH=Pseudoangiomatoid hyperplasia; IP=Intraductal papilloma.
doi:10.1371/journal.pone.0010240.t001
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Sample ID Gain* of DNA Loss* of DNA Copy-neutral LOH
08-352 1p36.31p13.2 2q31.1q32.1 6p21.33p21.32
1q21.1q41 4pterp15.2 12pterp12.1
2(triploid) 8pterp12 12q11.22
3q11.2 11q14.1q22.1 13q11q33.1
6q22.31q25.1 14
b 17pterp13.1
8q22.3q24.3 17
b Xq13.1q23
9p22.3p22.1 19
b
11q22.1q23.1 Xq25
12p11.21q12
13q33.2qter
14
a
15q25.2qter
17
a
18(triploid)
19
a
20q13.13q13.2
Xq23q26.2
09-091 8(triploid) 6q21, 6q16.1 22q11.21q11.22
10q22.3 13q21.31q21.33
22q11.23q12.1 21q21.1q21.2
09-118 5p15.2, 5p15.1p13.3 3q28q29
10q21.3 5p15.32, 5p15.2p15.1, 5p13.3
11p11.2p11.12 5q14.1
12p13.1p12.3 6q22.31q23.3, 6q25.3q26
12p12.1p11.22 10q21.1q21.2, 10q22.1q22.3, 10q24.1q26.3
12q12q13.11 12
c
15q21.1q21.3 14q31.1-q32.11, 14q32.13q32.2
18p11.32 15q14q21.1, 15q22.1q22.2
16p13.3p13.2
17q25.3
22q11.23q13.31
Xp22.33p22.11
Xq22.1q28
09-148 1q21.1, 1q21.3 5p14.3, 5p14.1 6q22.31
1q32.1q32.3 6q14.1, 6q24.1 22q13.31qter
5p15.2, 5p13.3p12 8q2.3, 8q22.3 Xq22.1q22.3, Xq22.3, Xq23
17q12, 17q21.32q21.33 8p23.2p23.3
17q22q23.3 13q21.1
20q13.31qter
09-301 2q21.3q22.1
4q31.21q31.22
5q21.3q22.1, 5q23.331.1
8q23.2
14q23.2q23.3
Cytological locations are listed as chromosome:arm:band(s);
*Gain (3 or more copies) or Loss (0 or 1 copy) of DNA .3 million base pairs; LOH=loss of heterozygosity.
amultiple regions of DNA gain;
bmultiple regions of DNA loss;
cmultiple regions of copy neutral (diploid) loss of heterozygosity.
doi:10.1371/journal.pone.0010240.t002
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activity was up regulated in the central region of the spheroid as
shown by strong fluorescence with LysoTracker Red
(Figure 3F&G) and distinct staining of LC3B and Atg5 by IHC
in FFPE tissue sections (Figure 3A & C). This is consistent with the
up-regulation of autophagy to promote survival in the hypoxic and
nutrient deprived center of the spheroid in culture or the
intraductal DCIS microenvironment.
Autophagy is required for emergence and survival of
DCIS tumorigenic spheroid cells
Treatment of DCIS cultured cells with chloroquine phosphate
(CQ, 50 mM), which disrupts autophagy, markedly suppressed
xenograft tumor formation. Zero of seven DCIS cultured cell strains
treated with CQ for greater than 4 days formed tumors, whereas 21
of 27 untreated cultured DCIS cell transplants yielded xenograft
Figure 2. Signal pathway mapping of DCIS organoid outgrowths by reverse phase protein microarray. The activation state of signaling
pathways in the DCIS spheroids was compared to the anchorage dependent cells in organoid culture to characterize the cell populations. 48 endpoints
were analyzed representing total or post-translationally modified proteins. Under direct microscopic visualization we procured spheroids, the epithelial
monolayer, and separate cuboidal monolayer cells from the same DCIS organoid culture. Approximately 25 spheroids were analyzed. Data was normalized
to b-Actin per microarray spot as described in VanMeter et al [19]. (A) Comprehensive depiction of cell signaling kinase activity for spheroids (green),
epithelial (blue) and cuboidal (red) cell populations (relative mean intensity, n=2). Autophagy markers (Atg5 and LC3B) were elevated in the spheroids in
comparison to theepithelial and cuboidal monolayer cells.p38 MAPKThr180/Tyr182 and SMAD2 Ser465/467, cell signaling proteinsassociated withsurvival
and stress were elevated in the spheroids in comparison to the epithelial and cuboidal monolayers. (B) The spheroids exhibited progenitor cell
characteristics as evidenced by augmentation of CD44, COX-2, and matrix metalloproteinase (MMP-14), with associated reduction of E-Cadherin. The
spheroids were found to be cytogenetically abnormal (Figures S4–S6) compared to the normal karyotype of the epithelial monolayer.
doi:10.1371/journal.pone.0010240.g002
Table 3. Immunohistochemical characterization of primary
patient breast tissue.
Sample ID Diagnosis LC3B Beclin1 Atg5 CD44
08-183 DCIS 1+ 3+ 3+ Positive
08-352 DCIS 1+ 3+ 3+ Positive
09-091 DCIS/ADH 0 1+ 1+ Negative
09-118 ADH* N/A 1+ 1+ Positive
09-148 DCIS 0 2+ 1+ Positive
09-301 DCIS 0 2+ 1+ Positive
09-327 DCIS 0 2+ 1+ Negative
DCIS=ductal carcinoma in situ; ADH=Atypical ductal hyperplasia.
*Previous history of DCIS, patient treated with Tamoxifen citrate.
doi:10.1371/journal.pone.0010240.t003
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propagated DCIS epithelial cells with CQ markedly suppressed
outgrowth, spheroid formation (Figure 4), and induced apoptosis
(elevation of cleaved PARP Asp214 (Figure S7)) as early as 48 hours
post treatment (Figure 4). CQ treatment suppressed autophagy
associated signal pathway endpoints in the DCIS progenitor cells,
including IRS-1 Ser612, AKT Thr308, ERK Thr202/Tyr204, and
p38 Thr180/Tyr182 (Figure S7). Statistically significant differences
that provide insights into the phenotype of the spheroids before and
after treatment with chloroquine treatment are shown in Figure 4E.
E-cadherin, Laminin5, Integrina5b1,FAK Tyr576/577,and MMP-
9, involved in extracellular matrix signaling, attachment and
degradation, were all suppressed following CQ treatment (Wilcoxon,
p=0.1). Atg5 and AMPKb1 Ser108, components of the autophagy
pathway, were suppressed, consistent with chloroquine disruption of
autophagy. The remaining adherent cells following CQ treatment
displayed lysosomal/autophagosome maturation arrest as evidenced
by increased punctate staining with LysoTracker Red (Figure 3H).
These data indicate that autophagy is required for the survival and
tumorigenicity of cultured DCIS spheroid forming cells.
Suppression of autophagy eliminates cytogenetically
abnormal spheroid forming DCIS cells and suppresses
their invasive phenotype
We examined the cytogenetics of CQ treated organ cultures.
The surviving cells after CQ treatment were found to be
cytogenetically normal (Figure S4 & S6). Thus even in an
organoid culture, with a mixed cellular population, the cytoge-
netically abnormal spheroid forming cells, which emerged within 4
weeks, were eliminated in the culture by CQ, while the surviving
cells retained the normal karyotype of the donor patient tissue. CQ
treatment blocked the autophagy pathway required for the
survival and 3-D growth of the cytogenetically abnormal
neoplastic cells. These data indicate that autophagy is required
for the survival of the spheroid forming cytogenetically abnormal
DCIS cells.
The untreated DCIS neoplastic epthelial cells grew in a
multilayered colony on autologous stroma, formed spheroids on
the surface of the colony (Figure 4 A&B) and invaded the
underlying stroma. Following treatment with CQ the epithelial
colony degenerated completely. For independent patient DCIS
lesions, CQ treatment administered to freshly explanted fragments
of ducts prevented any outgrowth of epithelial cells for at least one
month and was associated with degeneration of organoid
intraductal DCIS epithelial cells. CQ treatment, administered
after outgrowth had occurred for 2 weeks, markedly suppressed
epithelial expansion for independent cases (Figure 4). The mean
diameter of the outgrowth prior to treatment was 0.85 cm60.11
(n=15) and after chloroquine treatment, the mean diameter was
0.084 cm60.03 (n=23) (p,0.0001). In the second series of
organoid cultures, the mean diameter of the outgrowth prior to
treatment was 1.3660.25 cm (n=8) while the chloroquine treated
outgrowth mean diameter was 0.2160.03 cm (n=7) (p=0.0026)
(Figure 4C).
CQ treatment virtually abolished spheroid and 3-D growth. As
shown in Figure 4D for two different patient DCIS cases, the
number of spheroids generated post chloroquine treatment was
zero for the majority of explants, compared to up to 113 spheroids
generated per duct organoid in the untreated culture. The number
of spheroids generated in the untreated culture ranged from 1 to
more than 100 for individual duct fragments (mean of 38.7611;
n=14) (Figure 4D). Following chloroquine treatment, 12 out of 14
explants did not have any spheroids (mean number of spheroids
post treatment 0.2160.15; n=14; p=0.0049). CQ treatment
abolished spheroid outgrowth and survival in culture. These data
indicate that autophagy is necessary for the survival, growth, and
invasion of the cytogenetically abnormal, tumorigenic DCIS cells.
Discussion
Fresh human DCIS lesions reproducibly generate in vitro
anchorage independent, neoplastic epithelial cells that generate
3-D structures including spheroids and duct-like structures.
Neoplastic cells with this phenotype can emerge from a high
proportion of replicate DCIS lesion samples from the same
patient, and can be serially propagated for at least one year. No
anchorage independent cells arose from tissue containing
histologically verified normal appearing glands and adipose tissue.
The anchorage independent epithelial cells were observed to arise
from all grades of DCIS including ADH (Table 1).
The cytogenetically abnormal cells contained in fresh human
DCIS lesions are potentially malignant by the following criteria: a)
generation of neoplasms in NOD SCID mice, b) anchorage
independent 3-D structures that increase in size and frequency
over time, which can be subcultured for at least one year (Figure 1),
c) abnormal neoplastic-type cytogenetics (Table 2, Figures S4–S6),
and d) invasion of autologous stroma in the organ culture
(Figure 3–4).
It is unlikely that the neoplastic cell strains propagated from
fresh human DCIS ducts are isolates of micro-invasion areas or
invasive cancer in the original histopathology.The patient source
material was verified histologically to be devoid of microinvasion
or invasive cancer before and after DCIS lesion tissue procure-
ment. The verification was by an independent pathologist with no
knowledge of the research findings for the individual specimen.
The DCIS lesion source material was evaluated by IHC for type
IV collagen and was found to contain an intact basement
membrane (Figure S8). If the neoplastic, cytogenetically abnormal
cells isolated in this study represented areas of microinvasion, this
Figure 3. Autophagy is activated in human DCIS lesions and xenograft tumors and is inhibited with chloroquine.
Immunohistochemistry markers of autophagy were examined in primary DCIS lesions, mouse xenograft tumors, and DCIS ex vivo generated
spheroids/pseudoductal structures. Autophagy markers (Atg5, LC3B, Beclin1) exhibited prominent positive staining in primary DCIS lesions (Table 3).
(A) IHC of a primary DCIS lesion showing punctate staining within the cytoplasm for LC3B a protein associated with autophagosome formation (anti-
LC3B, 1006). (B) Beclin1 positive human DCIS derived mouse xenograft tissue (1006). (C) Case 08-352 surgical specimen is positive for Atg5 staining
in comedo DCIS human breast glands (DCIS) compared to adjacent non-neoplastic ductal elements (NL) (106). (D) Positive Atg5 staining of a DCIS
organoid after 12 weeks in culture (206). (E–H) Autophagy is also activated in cultured DCIS pseudoductal structures and spheroids. (E) A bright field
image of a multi-cellular pseudoductal structure (206). (F) Fluorescence microscopy shows accumulation of LysoTracker Red dye within the
organelles of the inner cell mass of the structure shown in panel E (206). (G) LysoTracker Red dye accumulation within the central cell mass of a
spheroid (red=LysoTracker Red; blue=DAPI nuclear counterstain, 206) demonstrates enhanced phagosome and lysosomal activity in the region of
the aggregate expected to be most hypoxic. (H) Chloroquine inhibits autophagy by preventing the fusion of autophagosomes and lysosomes in the
dynamic, multi-step autophagy cascade. An organoid culture was maintained in culture medium supplemented with chloroquine phosphate (50 mM)
for 2 weeks. Dissociation of the spheroid, and diffuse accumulation of LysoTracker Red in autophagic compartments and lysosomes were observed
(red=LysoTracker Red; blue=DAPI nuclear counterstain, 206, Nikon Eclipse TE200 microscope).
doi:10.1371/journal.pone.0010240.g003
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DCIS cells grow on the surface of autologous stroma, spontaneously form pedunculated spheroids with an area of central necrosis (arrow), and invade
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Generation of spheroids and 3-D structures arose spontaneously
from multiple, independent human DCIS duct tissue fragments
from the same patient and from different patients.
The propagated spheroid forming cells, generated from fresh
human DCIS tissue, were cytogenetically abnormal and were
associated with xenograft tumor formation. We hypothesize that
these cytogenetically abnormal cells pre-exist in the fresh human
DCIS duct. This hypothesis was supported by the results of the
Illumina 300,000 cytoSNP beadchip comparing the molecular
cytogenetics profile of the organoid, the epithelial and cuboidal
cultured monolayers, and the spheroids and 3-D structures grown
in the same mixed culture. It is well established that the transition
from normal to neoplastic growth involves deregulation at various
cellular levels including gene-specific mutational events, alterations
in signal transduction and growth control pathways, and
dysfunctional DNA synthesis and repair mechanisms resulting in
the generation of chromosomal abnormalities. At the chromo-
somal level, it is now accepted that some degree of copy number
variation (CNV) and copy-neutral loss-of-heterozygosity (LOH)
exists in the normal karyotype [22,23]. However, we have
observed in this study that cells with these features can rapidly
emerge during the time course of in vitro culture. The early
emergence of chromosomally abnormal cells may be the drivers of
the dominant neoplastic phenotype observed during DCIS culture
outgrowth.
Transformed cells containing regions of excessive CNV can
change the dosage of key regulatory genes and protein output;
while de novo regions of LOH can potentially expose harmful
recessive alleles. Of note was the strikingly similar loss on
chromosome 6 in the spheroid forming cells of three different
patients. This region on chromosome 6 narrowly encompasses the
SUPT3H gene (protein coding GIFtS:59, GC06M044904, Uni-
ProtKB/Swiss-Prot: SUPT3_HUMAN, O75486). Little is a
known about the encoded 399 amino acid protein. It is thought
to be a transcription factor, participating in the STAGA complex
(SPT3-TAF9-GCN5-acetylase) involved in p53 and c-Myc
regulation [24–26]. From this study, the genes contained within
affected chromosomal regions of gain or loss can be studied in
further detail to gain greater insight into the transformation
process. Higher density microarrays, gene expression studies, and
gene sequencing can be applied in candidate gene approaches
using these data as a starting point. Even in the case in which
different patients show different patterns of aberration, the same or
similar regulatory pathways related to cell survival, oxidative
stress, angiogenesis, or autophagy may be involved.
A strong rationale links autophagy to the survival and invasion
of pre-malignant breast cancer. The first link is hypoxia and
nutrient stress [27]. Proliferating ductal epithelial cells accumu-
lating within the breast duct do not have access to the vasculature
outside the duct. For this reason, high grade DCIS is associated
with central necrosis, and the accumulation of lipofuschin.
Autophagy is a pathway activated to promote survival in the
face of hypoxic and nutrient stress [17,28–30]. Consequently the
activation of autophagy may divert the hypoxic cells away from
apoptosis and thereby support the survival and growth of DCIS
neoplastic cells within the lumen [31]. The second link is anoikis,
the triggering of apoptotic cell death for cells that have been
separated from their normal adhesion substratum [32]. Normal
glandular epithelial cells require attachment to, or association
with, the basement membrane extracellular matrix (ECM) for
continued survival. During ductal hyperplasia and dysplasia
epithelial cells exist within the duct at a substantial distance away
from association with the peripheral basement membrane.
Moreover, invading carcinoma cells can migrate into the stroma
in the absence of a basement membrane anchor [33]. Autophagy
has been shown to be a key regulator of survival for cells deprived
of an anchoring substratum [32], and may play an important role
for cell survival in any anchorage independent state. A third link
is matrix degradation [29]. High grade DCIS, microinvasion, and
overt carcinoma invasion are associated with interruptions,
remodeling, and enzymatic breakdown of the basement mem-
brane and the stromal ECM [34,35]. Autophagy may facilitate
cell movement through areas of degraded matrix by the
phagocytic processing of matrix breakdown fragments [36]. A
fourth link is calcium. Microcalcifications are mammographic
indicators of high grade DCIS [37], and calcium phosphate
precipitates are potent inducers of autophagy [38]. Five out of
seven tissues used for ex vivo organoid culture were noted to have
microcalcifications.
The data presented herein, strongly support the conclusion that
autophagy plays a necessary role in the DCIS cell malignant
phenotype:
a) autophagy is up-regulated in the in vivo DCIS lesion as
shown by immunohistochemistry; b) autophagy is up regulated in
the cultured DCIS spheroids and 3-D structures, as shown by
immunohistochemistry and immunofluorescence; c) autophagy is
up-regulated in mouse xenografts as shown by immunohistochem-
istry; d) autophagy signal proteins are up-regulated in cultured
DCIS spheroids, with validation after long term culture, by reverse
phase protein microarray measurement; e) disruption of autoph-
agy by chloroquine phosphate (CQ) completely abrogated
xenograft tumor formation; f) CQ completely blocked growth
and invasion of DCIS cells on autologous stroma; g) CQ markedly
suppressed DCIS spheroid formation and outgrowth in culture for
independent experiments; and h) CQ completely eliminated
cytogenetically abnormal cells from the DCIS cultured cells.
Based on these established mechanistic roles, autophagy consti-
tutes a novel target for treating DCIS and arresting DCIS
transition to overt invasion.
the autologous stroma (arrow). (B) DCIS organoid cultured in the presence of chloroquine for 2 days showed complete absence of cellular outgrowths
anddegenerated cells within theduct (arrow) (106). (C)Chloroquine suppressed outgrowth of DCIS epithelial cellsin cultureas measured by outgrowth
diameter. Two axis diameters were measured for multiple organoids for two cases. Case 09-148-A mean diameter outgrowth prior to treatment (open
circle) was 0.85 cm60.11 (n=15, mean 6SEM) and after chloroquine treatment (black circle), the mean diameter was 0.084 cm60.03 (n=23, mean
6SEM) (p,0.0001). Case 09-148-B mean diameter outgrowth prior to treatment (open triangle) was 1.36 cm60.25 (n=8, mean 6SEM) while the
chloroquine treated outgrowth (black triangle) mean diameter was 0.21 cm60.03 (n=7, mean 6SEM) (p=0.0026). (D) The number of spheroids
generated in the untreated cultures (open circle, case 09-148) ranged from 1 to more than 100 for individual duct fragments (mean of 38.7611; n=14,
mean 6SEM).Followingchloroquinetreatment,12out of14explantsdidnot haveanyspheroids(meannumberofspheroidsposttreatment0.2160.15;
n=14; p=0.0049, black circle, mean 6SEM). For case 09-301, the mean number of spheroids prior to treatment was 20.567.8, n=14 (open triangle,
mean 6SEM) and there were no spheroids observed after treatment (n=3; black triangle, mean 6SEM). (E) Epithelial cells and spheroids were
maintained in culture, followed by treatment with chloroquine phosphate (50 mM) for 4 days. Spheroids were harvested pre and post chloroquine
treatment. Chloroquinemarkedlyinhibitedautophagy associatedpathwaysas shownby areductioninautophagypathwayproteins(Atg5 andAPMKb1
Ser108), adhesion proteins (E-Cadherin, Laminin5, Integrin a5b1, FAK Tyr576/577, MMP-9), and proliferation/prosurvival proteins (BAK, C-RAF Ser338,
p38 MAPK Thr180/Tyr182) (Wilcoxon p=0.1). (blue=untreated, red=chloroquine 50 mM; n=3, 6SEM).
doi:10.1371/journal.pone.0010240.g004
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in the face of oxidative, hypoxic and nutrient deprivation stress.
Our results indicate that autophagy is a requirement for the
survival and the malignant phenotype (tumorigenicity and
invasion) of cytogenetically abnormal cultured human DCIS cells.
It is possible that the observed genetic abnormalities directly or
indirectly induced the up-regulation of autophagy and thereby
promoted survival of the DCIS cells. It is also possible that
autophagy was not driven directly by the genetic changes. Instead
the malignant precursor cells up-regulated autophagy as a
necessary means to generate anchorage independent 3-D
structures such as spheroids and pseudo ducts. In either case,
the end result is the same: Autophagy is required for the observed
phenotype.
Chloroquine phosphate, which suppressed or abolished the
anchorage independent, cytogenetically abnormal anchorage
independent neoplastic DCIS cells, is an orally administered small
molecule inhibitor which blocks the autophagy pathway by
accumulating in autophagosomes and inhibiting autophagosomal
formation/function [17]. Chloroquine has been shown to suppress
N-methyl-N-nitrosurea induced mouse breast carcinomagenesis
[39], enhances the effectiveness of tyrosine kinase inhibitor
treatment of primary CML stem cells [40], and has been proposed
as a potential means to enhance the effectiveness of tamoxifen in
vitro in tamoxifen resistant breast carcinoma cells by blocking
autophagy dependent cell survival [17,28]. Moreover, chloroquine
has been proposed as a chemoprevention therapy for Myc induced
lymphomagenesis because it induces lysosomal stress that causes a
p53 dependent cell death that does not require caspase mediated
apoptosis [41].
These data provide additional evidence that the local ductal
tissue microenvironment influences the progression of in situ
carcinomas. Breast stromal cells [42], endothelial cells, and
myoepithelial cells [43] have been implicated in the transition
from in situ to invasive carcinoma. By IHC, Caveolin-1 was found
to be down regulated in stroma of DCIS lesions with a greater
incidence of subsequent invasive cancer [44]. Jedeszko et al [34]
reported that stromal fibroblasts contributed to the regulation of
invasion by the production of hepatocyte growth factor, using a
co-culture model with MCF10 and SUM102 cell lines. The
present study identifies and characterizes malignant precursor
epithelial cells in fresh human DCIS lesions, and therefore goes
beyond model systems using established cell lines such as MCF10.
Even though the cytogenetically abnormal DCIS epithelial cells
we have derived appear to have the characteristics of progenitor
cells by RPMA analysis (Figure 2 and Table S2), our method of
generating these cells is different than cell sorting methods used for
what are defined as ‘‘cancer stem cells’’. In the present study we
purposely did not assume that the DCIS neoplastic cells would be
positive for CD44 or any other surface marker. We did not
enzymatically dissociate the DCIS lesions and then conduct flow
sorting as has been done for studies of breast carcinoma [45–47].
Instead, we allowed the spheroid and 3-D ductal structures to
grow spontaneously from epithelial cells that emerged from
exposed open ends of the DCIS duct in organ culture. Thus, the
cytogenetically abnormal (Table 2) progenitor-type cells we have
identified are self-selected by anchorage independence in organ
culture. While there is broad evidence supporting the existence
and role of stem cells both in normal mammary gland
development and tumorigenesis [45–48], we cannot formally
classify these cells to be, or not to be, ‘‘cancer stem cells’’. This
classification is irrelevant to the fact that these propagated DCIS
lesion derived cells are cytogenetically abnormal and have
malignant characteristics.
In conclusion, fresh human DCIS organoid culture reveals
cytogenetically abnormal, neoplastic, anchorage independent cells
that require autophagy for survival. Invasive neoplastic cells may
pre-exist within the human breast DCIS duct but are apparently
held in check by the ductal niche, and can be coaxed to emerge in
organ culture when the duct is cut open. Blockade of the
autophagy pathway abolishes the propagation, invasion, and 3-D
growth of the DCIS neoplastic cells. The reproducible derivation
of cytogenetically abnormal cells with fresh human DCIS lesions
provides a new ex vivo model to study the biology of DCIS.
Moreover, the yield, and properties, of progenitor-like cells from
samples of human DCIS lesions following in vivo treatment of
DCIS can be used to screen the effectiveness of an in vivo therapy.
Finally, autophagy constitutes a new treatment target for DCIS.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki, with written informed patient
consent. The study was approved by the institutional review
boards of Inova Fairfax Hospital and George Mason University.
Animal care and use was approved by Institutional Animal Care
and Use Committee of George Mason University and the US
Department of Defense according to (a) DOD Directive 3216.1,
‘‘The Use of Laboratory Animals in DOD Programs’’, (b) US
Army Regulation 40–33, ‘‘The Care and Use of Laboratory
Animals in DOD Programs’’, and (c) Animal Welfare Regulations
(CFR Title 9, Chapter 1, Subchapter A, Parts 1–3).
Tissue collection
Fresh, sterile breast DCIS tissue was obtained from patients
undergoing standard of care surgery for suspected or biopsy
confirmed neoplasia at Inova Fairfax Hospital, Falls Church, VA
(Table 1). Written informed consent was obtained prior to tissue
procurement according to the provisions of the Declaration of
Helsinki and Inova Health System institutional review board.
Gross tissue pathology at the time of procurement was assessed by
a board certified pathologist (LP, SZ, GM, JM, JJ). Tissue
containing DCIS lesions was excised for further macrodissection.
Ductal tissue was dissected from surrounding breast adipose/
fibrous tissue of the surgical specimen. The ductal tissue was rinsed
in serum free DMEM/F12 medium (Invitrogen, Carlsbad, CA)
prior to distribution in culture flasks.
Organoid culture of fresh human DCIS lesions
The tissue was dissected into organoids approximately 3 mm
2,
containing one or more discernable duct segments with associated
stroma. Dissected breast ductal tissue was grown in serum free
DMEM/F12 medium supplemented with human recombinant
EGF (10 ng/mL; Cell Signaling Technology, Danvers, MA),
insulin (10 mg/mL; Roche, Indianapolis, IN), streptomycin sulfate
(100 mg/mL; Sigma, St. Louis, MO) and gentamicin sulfate
(20 mg/mL; Sigma), with or without 0.36% (v/v) murine
Engelbreth-Holm-Swarm (EHS) derived, growth factor reduced,
basement membrane extract (Trevigen, Gaithersburg, MD) at
37uC in a humidified 5.0% CO2 atmosphere. Medium was
replaced three times per week. Organoids were submerged in a
minimum volume of medium (just enough to cover the duct
fragments) to maximize gas exchange. Non-adherent organoids
were removed from the culture flask. Cultures were maintained
continuously for up to one year. Periodically, organoids were
removed, under microscopic visualization, for propagation into
new culture flasks or phenotypic and molecular analysis.
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Autophagy was inhibited in organoid cultures by treating
cultures with chloroquine diphosphate (CQ) (50 mM; Sigma) in
DMEM/F12 medium as described above. CQ-containing medi-
um was replaced three times per week for a period of 6 months.
Comparable untreated control cultures were maintained in
identical medium lacking chloroquine with similar media changes.
Murine xenograft generation
Human DCIS tumor tissue, propagated organoid tissue, or
spheroids generated from primary DCIS organoid cultures were
transplanted transdermally into the mammary fat pad of female
NOD/SCID mice (NOD.CB17-Prkdc
scid/NCrHsd; Harlan or The
Jackson Laboratory) with a 17b Estradiol pellet (Innovative
Research of America, Sarasota, FL; 60 day release, 1.7 mg/
pellet). The DCIS organoids, prior to transplantation into the
murine mammary fat pad, were incubated in DMEM/F12
medium supplemented with EGF, insulin, streptomycin, gentami-
cin, or estrogen (Sigma) for 6 to 18 hours. The study was
conducted under a contract with Biocon Inc., Rockville, MD.
Survival, weight, and condition of all mice were monitored daily
and palpable tumor masses were measured with calipers (length/
width) twice weekly. Mice exhibiting evidence of tumor growth
were sacrificed as necessary or after 120 days. Complete
necropsies were performed for evidence of metastasis. Tumor
tissue, when present, was either excised for immunohistochemical
analysis or injected into a different NOD SCID mouse for
propagation of the tumor.
Immunohistochemistry
Formalin fixed murine tissue or DCIS organoids were processed
and paraffin embedded by commercial laboratories (AML
Laboratories, Inc, Rosedale, MD or Bi-Biomics, Nampa, ID).
Formalin fixed paraffin embedded (FFPE) tissue sections (5 mmo r
1 mm thickness) mounted on positively charged glass slides were
baked at 56uC for 20 min., deparaffinized in xylene and
rehydrated in a series of graded alcohols (100%, 95%, and 70%)
with a final rinse in wash buffer (Dako, Carpinteria, CA).
Immunostaining was performed on a Dako Autostainer with an
Envision+HRP staining kit (Dako) per manufacturer’s instructions
(Table S3). Stained tissue sections were counterstained with
Hematoxylin (Dako). Images were captured with an Olympus
BX51 microscope using 106,2 0 6, or 1006objectives.
Immunofluorescence and confocal imaging
Spheroids were aspirated directly from the culture flask under
direct microscopic visualization, mounted on positively charged glass
microscope slides, fixed in 16% paraformaldehyde (Fisher Scientific),
and stored dessicated at 4uC. FFPE murine xenograft tissue sections
were deparaffinized in xylene, and rehydrated in graded alcohols.
Spheroids and FFPE sections were incubated at room temperature
with anti-human specific epithelial antigen conjugated to FITC
(EpCAM-FITC, 5 mg/mL) (Abcam, Cambridge, MA), or mouse
immunoglobulin IgG1 as a negative control (Dako). Slides were
rinsed in borate buffer pH 8, then nuclear counterstained with
ProLong Gold+DAPI (Invitrogen). Images were captured with a
Nikon Eclipse C1si confocal microscope in different channels for
EpCAM-FITC (pseudo-colored green, 488 nm) and DAPI (psuedo-
colored blue, 408 nm) using the 206objective.
Autophagosome/lysosome imaging
LysoTracker Red (Invitrogen; 75 nM) and nuclear counterstain
Hoechst 33258 pentahydrate (Invitrogen; 5 mg/mL) were added to
DMEM/F12 culture medium as described above and incubated
with live human DCIS organoid cell cultures for 0.5 hour.
Medium containing dye was removed and replaced with fresh
medium. Images were captured with either a Nikon Eclipse C1si
confocal or a Nikon Eclipse TE200 microscope in different
channels for LysoTracker Red (psuedo-colored red, 561 nm) and
Hoechst 33258 (pseudo-colored blue) using either the 106or 206
objective.
Cell signaling pathway mappping by reverse phase
protein microarray (RPMA)
Cellular outgrowths were removed from the culture flask by
scraping or aspiration with a pipette and were spun briefly to pellet
the cells. Medium was removed by aspiration and the cell pellet
was subjected to lysis with a 10% (v/v) solution of Tris(2-
carboxyethyl)phosphine (TCEP; Pierce, Rockford, IL) in Tissue
Protein Extraction Reagent (T-PER
TM, Pierce)/Tris-glycine 2X
SDS buffer (Invitrogen). Cell lysates were stored at –80uC prior to
microarray construction. Cellular lysates were printed on glass
backed nitrocellulose array slides (FAST Slides, Whatman,
Florham Park, NJ) using an Aushon 2470 arrayer (Aushon
BioSystems, Burlington, MA) equipped with 350 mm pins as
previously described [49]. Immunostaining was performed as
previously described on a Dako Autostainer per manufacturer’s
instructions (CSA kit, Dako) [49]. Each slide was incubated with a
single primary antibody at room temperature for 30 minutes.
Polyclonal and monoclonal antibodies are listed in Table S1.
Antibodies were validated by western blotting as previously
described [19]. The negative control slide was incubated with
antibody diluent. Secondary antibody was goat anti-rabbit IgG
H+L (1:7,500) (Vector Labs, Burlingame, CA) or rabbit anti-
mouse IgG (1:10) (Dako). Subsequent signal detection was
amplified via horseradish peroxidase mediated biotinyl tyramide
deposition with chromogenic detection (Diaminobenzidine) per
manufacturer’s instructions (Dako).
Total protein per microarray spot was determined with a Sypro
Ruby protein stain (Invitrogen/Molecular Probes) per manufac-
turer’s directions and imaged with a CCD camera (NovaRay,
Alpha Innotech, San Leandro, CA).
Molecular Cytogenetics
Cellular outgrowths were removed from the culture flask by
scraping or aspiration with a pipette and were spun briefly to pellet
the cells. Culture medium was removed by aspiration and the cell
pellet was immediately frozen on dry ice and stored at –80uC prior
to nucleic acid extraction. Nucleic acid preparations derived from
human breast tissue and/or cell culture out growths were tested
using quantitative PCR (qPCR), PicoGreen (Invitrogen) staining
and fluorometry (FLx800 fluorescence plate reader, BioTek,
Winooski, VT). Microarray-based genomic analysis was per-
formed using CytoSNP-12 beadchips (Illumina, Inc.) and analyzed
on an Illumina BeadStation 500 GX laser scanner [50–52].
Briefly, the microarray process involved sample DNA amplifica-
tion, followed by DNA fragmentation, hybridization of samples to
beadchips, single-nucleotide extension, antibody-based labeling,
and finally two-color fluorescence scanning and computer-based
raw data collection.
The DNA extraction and purification was performed using a
DNA purification column (QIAmp DNA Mini Kit, Qiagen,
Valencia, CA). Approximately 200 ng of DNA at a concentration
of 50 ng/mL was amplified, fragmented, precipitated, re-suspend-
ed, and hybridized to the Illumina CytoSNP-12 beadchips. After
single-base extension, sample DNA was stained and the chip was
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and copy number values.
Raw fluorescence data was converted to genotypic data using
the Illumina GenomeStudio software program. Data analysis was
performed using the Illumina KaryoStudio software program that
converts genotypic and signal intensity data into a ‘‘molecular
karyotype’’ showing B allele frequency, Log R ratio, LOH score
and Copy Number Score. Log R ratio, which is the log (base 2)
ratio of the normalized R value for the particular SNP divided by
the expected normalized R value, was employed. The red line in
the log R plot indicates a smoothing series with a 200 kb moving
average window. Thus, a Log R Ratio\2 was considered to
represent a true amplification and Log R Ratio\-1.5 was
considered to represent a probable homozygous deletion.
Additionally, B allele frequency data was used to identify regions
of copy-neutral and hemizygous LOH.
Statistics
Standard deviation (SD) or standard error of the mean (SEM)
was calculated for small group comparisons. The Student t-test,
two tailed with Welch’s correction, was used to calculate the p-
value, and to determine the statistical difference of epithelial
outgrowth area before and after CQ treatment and spheroid
generation. P values ,0.05 were considered significant (GraphPad
Prism ver 5.03, GraphPad Software). Wilcoxon rank sum was used
to determine the differences between CQ treated and untreated
groups for the reverse phase protein arrays (R, SAS Institute). A
p=0.1 was considered different for small sample sizes.
Supporting Information
Figure S1 Macroautophagy cell signaling pathway. Autophagy
(auto - self, phagy - eating) is a catabolic process that can either
maintain cellular homeostasis or result in cell death. Intracellular
signaling kinases such as AKT, PI3 Kinase, ERK, Bcl-2, and
mTOR regulate autophagy. Reverse phase protein microarrays
(RPMA) were employed in the present study to evaluate the
activation (phosphorylation) of signal pathway proteins that are
associated with autophagy. Pathway diagram reproduced courtesy
of Cell Signaling Technology, Inc. (www.cellsignal.com).
Found at: doi:10.1371/journal.pone.0010240.s001 (0.93 MB TIF)
Figure S2 Human DCIS xenograft tumor histology. H&E
staining of mouse xenograft tumor derived from fresh human
DCIS cells. (A) Human DCIS explant derived mouse tumor (20x).
(B) Xenograft tumor is comprised of pleomorphic epithelial cells
with prominent nucleoli and partial ductal/glandular differentia-
tion directly abutting or invading surrounding stroma (40x).
Found at: doi:10.1371/journal.pone.0010240.s002 (7.27 MB TIF)
Figure S3 Molecular karyotype of chromosome 6 from human
cultured DCIS cells shows a deletion p21.1/12.3. The upper
panels show the log R ratio plots from 3 different patients (top: 09-
148 spheroids/3-D structure; middle: 08-352 3-D structure;
bottom: 09-091 spheroids/3-D structure). These data represent
DNA ploidy, or copy number, for the displayed chromosomal
region with the red line indicating the statistical average value. A
log R ratio of 0.0 equals a DNA copy number of 2 (diploid).
Deflection downward of the red line indicates loss of DNA copy
number. Each blue dot represents the log R ratio value for each
SNP. The shaded regions represent segments of DNA deviating
from a copy number of 2 as determined by the Illumina
GenomeStudio 2.0 software. The software uses both quantitative
fluorescence intensity and qualitative genotypic data for deter-
mining copy number values. The color code is as follows: orange
indicates a region of 1 copy; red, 0 copies; blue, 3 copies; purple, 4
or more copies; and green, copy-neutral LOH (2 copies). The
center panel shows the chromosomal ideogram indicating
cytological bands with the centromere in red. The small window
shows the region expanded in the figure and the nucleotide
positions for this region are shown below the ideogram. The lower
panel shows the cytogenetic bands and genetic map for genes
located in the expanded region. Note that the region of the
deletion for these 3 patients (orange) corresponds to the transcript
for SUPT3H.
Found at: doi:10.1371/journal.pone.0010240.s003 (0.18 MB TIF)
Figure S4 Molecular karyotype of chromosome 5 from
chloroquine treated or untreated cultured human DCIS cells.
The upper panel shows log 2 ratio plots of 2 different samples from
the same patient (top: 09-148 chloroquine treated epithelial
monolayer; bottom: 09-148 untreated spheroids/3-D structure). In
the upper panel, the top plot shows the log R ratio from
chloroquine treated human DCIS cell cultures showing normal
ploidy, while the lower plot shows a number of extended regions of
gain and loss of content on chromosome 5. The color code is as
follows: orange indicates a region of 1 copy; red, 0 copies; blue, 3
copies; purple, 4 or more copies; and green, copy-neutral LOH (2
copies). Blue and purple regions show an increase of copy number
extending from nucleotide position ,31 Mb to ,43 Mb (12 Mb
in total) affecting the dosage of numerous genes. Additional
regions of copy number gain are present distally, including
subtelomeric regions. Extended regions of copy number loss are
indicated in orange (one copy) and red (0 copy). The lower panel
shows the cytogenetic banding pattern and the corresponding
nucleotide positions beginning with the p-telomere.
Found at: doi:10.1371/journal.pone.0010240.s004 (0.22 MB TIF)
Figure S5 Allele frequency of chromosome 17 q-arm for
spheroids from DCIS organoid culture. Molecular karyotype of
chromosome 17 q arm. The upper panel shows log R ratio and B
allele frequency plots of genomic DNA from an organoid sample
(case 09-148 spheroids/3-D structure). The top plot shows an
upper deflection of the red averaging line indicating a gain in copy
number (blue) spanning ,14 Mb of chromosomal content. This is
the largest of multiple gain of copy number regions on the q-arm
in this neoplastic sample (data not shown). The bottom plot shows
the B allele frequency data for this same region. Within the blue
shaded region, the B allele frequency data for heterogeneous SNPs
(normally at 0.5 for diploid) is split into 2 lines at values above and
below 0.5, indicating the presence of 3 copies of DNA in this
region, consistent with the log 2 ratio data shown above. The
bottom panel shows the chromosome 17 ideogram with the
expanded region outlined below. The gain of DNA copy number
extends from q22 to q24.3.
Found at: doi:10.1371/journal.pone.0010240.s005 (0.15 MB TIF)
Figure S6 Molecular karyotype of chromosome 6 from
chloroquine treated or untreated cultured human DCIS cells.
Molecular karyotype of chromosome 6 from chloroquine treated
cultured DCIS epithelial monolayer devoid of spheroids and
untreated spheroids for case 09-148. Molecular karyotype of
chromosome 6; p21.1/p12.3: The upper panel shows the log R
ratio plots from 2 different samples from the same patient. In the
upper panel, the top plot shows the log R ratio from cell cultures
treated with chloroquine phosphate showing normal ploidy, while
the lower plot shows a hemizygous deletion (orange) of the
SUPT3H locus in cultures displaying spheroid and 3-D structures.
This data represents DNA ploidy, or copy number, for the
displayed chromosomal region with the red line indicating the
statistical average value. A log R ratio of 0.0 equals a DNA copy
Autophagy Regulation of DCIS
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indicates loss of DNA copy number. Each blue dot represents the
log R ratio value for each SNP. The shaded regions represent
segments of DNA deviating from a copy number of 2 as
determined by the Illumina GenomeStudio 2.0 software. The
software uses both quantitative fluorescence intensity and
qualitative genotypic data for determining copy number values.
The color code is as follows: orange indicates a region of 1 copy;
red, 0 copies; blue, 3 copies; purple, 4 or more copies; and green,
copy-neutral LOH (2 copies). The center panel shows the
chromosomal ideogram indicating cytological bands with the
centromere in red. The small window shows the region expanded
in the figure and the nucleotide positions for this region are shown
below the ideogram. The lower panel shows the cytogenetic bands
and genetic map for genes located in the expanded region.
Found at: doi:10.1371/journal.pone.0010240.s006 (0.58 MB TIF)
Figure S7 Signal pathway alterations induced by chloroquine
treatment of cultured DCIS spheroids. Complete set of cell
signaling kinases measured by reverse phase protein microarray
for the subset shown in Figure 4. Chloroquine markedly inhibited
autophagy associated pathways as shown by a reduction in
autophagy pathway proteins (Atg5 and APMKb1 Ser108),
adhesion proteins (E-Cadherin, Laminin5, Integrin a5b1, FAK
Tyr576/577, MMP-9), and proliferation/prosurvival proteins
(BAK, C-RAF Ser338, p38 MAPK Thr180/Tyr182) (blue bar -
untreated, red bar - chloroquine treated (50 mM), n=3, 6SEM;
Wilcoxon p=0.1).
Found at: doi:10.1371/journal.pone.0010240.s007 (0.46 MB TIF)
Figure S8 Basement membrane remains intact in DCIS
cultured organoids. Collagen type IV immunohistochemistry
demonstrates intact basement membrane surrounding breast ducts
(brown staining). (A) Case 08-352 FFPE primary breast tissue at
time of procurement. Scale bar 100 mm, magnification 106. (B)
The basement membrane remains intact surrounding the duct
that is within the tissue fragment and surviving after the breast
organoid was growing in culture for 12 weeks (case 08-148,
magnification 206).
Found at: doi:10.1371/journal.pone.0010240.s008 (2.39 MB TIF)
Table S1 Validated primary antibodies for Reverse Phase
Protein Microarray analysis.
Found at: doi:10.1371/journal.pone.0010240.s009 (0.03 MB
XLS)
Table S2 Verification of DCIS progenitor cell phenotype:
Reverse Phase Protein Microarray analysis of DCIS cultured
epithelial cells, spheroids and stromal fibroblasts.
Found at: doi:10.1371/journal.pone.0010240.s010 (0.04 MB
XLS)
Table S3 Primary antibodies and antigen retrieval conditions for
immunohistochemistry.
Found at: doi:10.1371/journal.pone.0010240.s011 (0.03 MB
DOC)
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